Emergent BioSolutions Inc.EBS

NYSEHealthcarePharmaceutical Preparations
Price (close)
$6.79
Market cap
$348.1M
P/E
—
Revenue (TTM)
$770.2M
Net income
-$176.8M
Dividend yield
—
1-year total return
-22.3%
Net margin
-23.0%
Revenue growth
-9.6%
Debt / equity
1.70x

What Emergent BioSolutions Inc. does.

We are a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate and naturally occurring Public Health Threats (“PHTs”). Our solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (“CDMO”) services portfolio. The types of PHTs we are currently addressing are focused on the following four categories:

Our revenues are derived from a combination of the sale and procurement of our product/product candidate portfolio (described below), the provision of our bioservices to external customers, and non-dilutive contract and grant funding for research and development ( “ R&D ” ) projects from various third-party sources.

As of December 31, 2025, the Company has a portfolio of 11 products focused on addressing global public health threats like smallpox, mpox, anthrax, Ebola and opioid overdose emergencies. The revenues generated by the products comprise a substantial portion of our revenue. We structure our business with a focus on markets and customers. As such, the key components of the business structure include the following four product and service categories: Commercial products, consisting of NARCAN ® Nasal Spray and KLOXXADO ® , Anthrax – Medical Countermeasures (“MCM”) Products, Smallpox - MCM products, and Emergent Bioservices (CDMO) (“Bioservices”).

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$1.6B$1.8B$1.1B$1.0B$1.0B$742.9M
Net income$305.8M$219.5M-$211.6M-$760.5M-$190.6M$52.6M
Free cash flow$395.0M$96.1M-$149.9M-$257.9M$35.8M$156.8M

More on EBS.

Figures from Emergent BioSolutions Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.